Characterization of the Interaction of Daptomycin With Site II on Human Serum Albumin.
Binding site
Daptomycin
Human serum albumin
Protein binding
Site II
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
23
03
2020
revised:
27
05
2020
accepted:
08
06
2020
pubmed:
23
6
2020
medline:
22
6
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
Daptomycin, a cyclic lipopeptide antibiotic, is clinically used for the treatment of infections caused by Gram-positive bacteria, including the methicillin-resistant Staphylococcus aureus and the vancomycin-resistant Enterococci. While daptomycin shows high plasma protein binding (90-93%), our knowledge of the binding process is not extensive. To address this issue in more detail, we characterized the binding of daptomycin to plasma proteins and the findings indicate that the association constant for the binding of daptomycin to human serum albumin (HSA) is much higher than that for α
Identifiants
pubmed: 32565355
pii: S0022-3549(20)30323-3
doi: 10.1016/j.xphs.2020.06.011
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Daptomycin
NWQ5N31VKK
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2919-2924Informations de copyright
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.